Alzheimer’s Disease – Not an Exaggeration of Healthy Aging
Open Access
- 1 July 2011
- journal article
- review article
- Published by SAGE Publications in Indian Journal of Psychological Medicine
- Vol. 33 (2), 106-114
- https://doi.org/10.4103/0253-7176.92047
Abstract
The world population is becoming older now. The boom of the elderly population comes from public health efforts to improve living conditions and prevent disease, and from improved medical interventions. People more than 65-year-old who are representing 12.9% of the population now is expected to grow to be 19% of the population by 2030. Very few numbers of diseases will have such socioeconomic burden on society in the newer world. Although Alzheimer's disease (AD) has been studied very well recently, still its exact etiopathogenesis is unknown. Currently there are no available tests for the definitive diagnosis of AD. So the clinical diagnosis of AD remains a diagnosis of exclusion. This limits the potential for early intervention. The difference between normal degenerative processes of brain and preclinical changes of AD is a gray zone and there is no particular way to distinguish between the two. Now several modalities like functional magnetic resonance imaging (fMRI), positron emission tomography (PET) scan, electrophysiological tests and cerebrospinal fluid (CSF) biomarkers for tauopathy and Aβ have shown to be promising in the development of early diagnostic tools for neurodegenerative changes and help us to differentiate between healthy aging and pathological aging. In this article we tried to discuss about the differences between pathological and physiological aging process from radiological, pathological, biochemical, and electrophysiological point of view. However, differentiating between physiological and pathological dementia still remains a challenge.Keywords
This publication has 79 references indexed in Scilit:
- Effects of Age on the Glucose Metabolic Changes in Mild Cognitive ImpairmentAmerican Journal of Neuroradiology, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Callosal atrophy in mild cognitive impairment and Alzheimer's disease: Different effects in different stagesNeuroImage, 2010
- When does age-related cognitive decline begin?Neurobiology of Aging, 2009
- Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer diseaseNeurology, 2009
- EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysisBrain Research Reviews, 1999
- Age-related changes in nicotinic acetylcholine receptor subunits α4 and β2 messenger RNA expression in postmortem human frontal cortex and hippocampusNeuroscience Letters, 1998
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- Neurochemical Studies of Early-Onset Alzheimer's DiseaseThe New England Journal of Medicine, 1985
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984